{"id":5383,"date":"2019-04-19T09:41:23","date_gmt":"2019-04-19T07:41:23","guid":{"rendered":"https:\/\/www.aieop.org\/web\/?p=5383"},"modified":"2019-04-19T09:42:16","modified_gmt":"2019-04-19T07:42:16","slug":"documento-dinutuximab","status":"publish","type":"post","link":"https:\/\/www.aieop.org\/web\/documento-dinutuximab\/","title":{"rendered":"Documento Dinutuximab"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 blog-article nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-padding-right:120px;--awb-padding-left:120px;--awb-margin-top:60px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-one-full fusion-column-first fusion-column-last\" style=\"--awb-bg-size:cover;--awb-margin-bottom:0px;\"><div class=\"fusion-column-wrapper fusion-flex-column-wrapper-legacy\"><div class=\"fusion-title title fusion-title-1 fusion-title-text fusion-title-size-two\"><h2 class=\"fusion-title-heading title-heading-left\" style=\"margin:0;\">Documento Dinutuximab<\/h2><span class=\"awb-title-spacer\"><\/span><div class=\"title-sep-container\"><div class=\"title-sep sep-double sep-solid\" style=\"border-color:#e0dede;\"><\/div><\/div><\/div><div class=\"fusion-text fusion-text-1\"><p>Gentili Soci,<\/p>\n<p>La presente per informarvi che nell\u2019area documentale del sito AIEOP, tra i documenti del GdL Neuroblastoma, potete trovare pubblicato il documento tal titolo: Dinutuximab.<br \/>\nSi tratta di un documento di recente nascita in cui sono delineati i pazienti per cui \u00e8 indicata l&#8217;immunoterapia con anti GD2 e definito pi\u00f9 nel dettaglio le definizioni di pazienti responsivi-refrattari o recidivi alla terapia.<\/p>\n<\/div><div class=\"fusion-clearfix\"><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":8,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-5383","post","type-post","status-publish","format-standard","hentry","category-in-evidenza"],"_links":{"self":[{"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/posts\/5383","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/comments?post=5383"}],"version-history":[{"count":2,"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/posts\/5383\/revisions"}],"predecessor-version":[{"id":5385,"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/posts\/5383\/revisions\/5385"}],"wp:attachment":[{"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/media?parent=5383"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/categories?post=5383"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aieop.org\/web\/wp-json\/wp\/v2\/tags?post=5383"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}